- Download PDF Copy
Reviewed
May 29 2024Cellular Origins
Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organization specializing in the advancement of the cell and gene therapy industry, today announced a collaboration to demonstrate universal automation of CGT manufacturing.
The partnership will undertake the physical and digital integration of existing bioprocessing equipment at the CGT Catapult’s Stevenage Manufacturing Innovation Centre (MIC) using Cellular Origins’ robotic platform, Constellation™. By bringing together CGT Catapult’s expertise in GMP operations and optimization with Cellular Origins’ Constellation, the goal will be to evidence the benefits of automation in real-world applications and advance the fields’ understanding of how automation can impact the barriers to scale that have held progress back.
2023 was a landmark year for the CGT industry, further demonstrating the growing need to scale CGT manufacturing. With a total of seven therapies receiving FDA approval—a number predicted to rise even further in 2024. In addition, increasing recommendations from regulators for CGTs to be used as earlier line treatmentswill likely see the sector transition from treating thousands to up to 10’s or 100’s of thousands of patients in the coming years. Despite the anticipated surge in demand, a lack of capabilities to efficiently manufacture these therapies at scale has led to a widening divide between the number of doses produced and the number of patients that could benefit from them.
The unique benefit of Constellation is universal automation that fluidically and digitally integrates a wide range of existing bioprocessing equipmentwith minimal change to both the biological process and the bioprocessing equipment. Constellation’s use of automated tube welding allows it to adapt to the process, consumables, and equipment rather than the other way around and without the need to add new components or connectors. This enables therapy developers to scale their CGT therapy and treat greater patient numbers without the delays and risk of re-developing their manufacturing process.
Constellation will be based at the CGT Catapult’s Stevenage MIC in its digital and automation testbeds, a newly developed pre-Good Manufacturing Practice (GMP) space for collaborators to develop digital and automated solutions to challenges that arise in the manufacturing of advanced therapies. The Stevenage MIC is a GMP-compliant facility licensed for clinical and commercial ATMP production, focused on developing manufacturing processes at scale, speed, and according to GMP.
The CGT Catapult is a world-leading specialist in the field of cell and gene therapy, and we are delighted to announce this collaboration, enabling us to access their expertise and leverage the full potential of Constellation to revolutionize CGT manufacturing at scale. CGT Catapult’s experience in establishing GMP facilities and optimizing cell therapy manufacture is directly aligned with Cellular Origins’ mission to prove the impact automated manufacturing can have in transforming cell therapy production.Through this partnership, we will work to demonstrate an automated manufacturing approach that will provide a route for patients worldwide to access these life-saving therapies.
Dr.Edwin Stone, CEO,Cellular Origins
Related Stories
- Investigating the evolution of cell division mechanisms in Ichthyosporea
- Heart healthy behaviors may slow biological aging, research shows
- Gene cluster expression analysis for personalized lung cancer therapy
Matthew Durdy, Chief Executive at the CGT Catapult, added:“Embracing automation is a key step that the cell and gene therapy industry must take to reduce costs, increase efficiency, and meet the growing demand for advanced therapies.”He added:“Through working with leading robotics and software experts such as Cellular Origins, we aim to develop new strategies that increase levels of automation. This will help our collaborators access the benefits of these technologies, help make advanced therapies more affordable to healthcare systems, and help more patients receive life-changing therapies.”
Source:
Posted in: Medical Science News
Tags: Automation, Bioprocessing, Cell, Gene, Gene Therapy, GMP, Healthcare, Manufacturing, Software, Technology
Comments (0)
- Download PDF Copy
Suggested Reading
Study explores how different modes of cell division evolved in close relatives of fungi and animals
Mouse study finds PFAS exposure in fathers disrupts offspring's gene expression
Researchers produce advanced multidimensional maps of gene regulation networks in the brain
Study finds Plexin-B1 could be key to Alzheimer’s treatment, enhancing glial cell response
Researchers develop mathematical model to predict effective dosage range of cancer treatment
Study sheds new light on the intricate molecular mechanisms underlying schizophrenia
Study reveals ferroptosis as a major driver of severe COVID-19 lung damage
New stem cell transplant approach may expand donor pool for high-risk blood cancer patients
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Login
(Logout)
Post
Terms
While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.
Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.
Please do not ask questions that use sensitive or confidential information.
Read the full .